Study to Evaluate Safety and PK/PD of DA-3091 in Healthy Male Subjects

• Status: Completed
• Trial end date: 1969-12-31
• Target enrollment: 0
• Participant gender: Male

Summary

This Phase I clinical study is to evaluate the safety and tolerance of DA-3091 and to characterize the pharmacokinetic/pharmacodynamic of DA-3091 in healthy male subjects

• Phase: Phase 1
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: Dong-A Pharmaceutical Co., Ltd.
• Treatments: Exenatide

Criteria

Inclusion Criteria:

1. Age : 20 ~ 45 years old

2. Healthy Male

3. Body weight : ≥50kg and Ideal body weight ± 20%

4. Informed consent

Exclusion Criteria:

1. Clinically significant medical history

2. Acute or Chronic pancreatitis

3. Clinically significant hypersensitivity of Drugs

4. Clinically significant cutaneous disorder

5. History of administration of exenatide

6. Disorder of blood pressure

7. History of drug abuse